Skip to content
Screener

Nektar Therapeutics NKTR Operating Lease Liabilities (Current)

Operating Lease Liabilities (Current) at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$37.8M+24.8%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$7.63M+2.2%
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
$3.14M-21.1%
Artiva Biotherapeutics, Inc. logo
Artiva Biotherapeutics, Inc.ARTV
$3.3M-6.7%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
$722K+30.6%
Vor Biopharma logo
Vor BiopharmaVOR
$307K-92.8%

Other financials

Income statement

See full
Revenue$10.9M+3.8%
Gross profit$21.8M+2.9%
Operating income-$39.1M+12.3%
Net income-$44.9M+11.7%
EPS (diluted)-$1.82+49.7%

Balance sheet

See full
Cash & equivalents$5.7M-20.0%
Total debt$83.2M-17.1%
Total equity$576.2M+4,094%
Total assets$763.3M+198%

Cash flow

See full
Operating cash flow-$44.3M+9.7%
CapEx$18.0K+800%
Free cash flow-$44.3M+9.7%

Valuation

See full
Market cap$2.58B+565%
Enterprise value$2.66B+456%
P/S46.5×+41.3×

Profitability

See full
Gross margin100%+31.2pp
Operating margin-242%—
Net margin-284.2%+937pp
FCF margin-366.6%+1,421pp

Returns & leverage

See full
Return on equity-53.6%-22.6pp
Debt / equity0.1×-7.2×
Current ratio10.2×+7.0×

Where this comes from

Reported directly by Nektar Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityCurrent.

The source filing: Nektar Therapeutics’s 10-Q, filed May 8, 2026.

Filed
May 7, 2026, 8:00 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-212596
Line itemMarch 31, 2026December 31, 2025
Current liabilities:
Accounts payable (including $504 and $137 as of March 31, 2026 and December 31, 2025, respectively, to a related party)$10,026$10,770
Accrued expenses (including $1,148 and $994 as of March 31, 2026 and December 31, 2025, respectively, to a related party)25,15122,271
Operating lease liabilities, current portion22,53120,495
Total current liabilities57,70853,536
Operating lease liabilities, less current portion60,63165,256
Liabilities related to the sales of future royalties, net60,27063,157
Other long-term liabilities8,4468,625

Item 1. Condensed Consolidated Financial Statements—Unaudited:

FAQ

What is Nektar Therapeutics's operating lease liabilities (current)?
Nektar Therapeutics (NKTR) reported operating lease liabilities (current) of $22.53M in Q1 2026.
How has Nektar Therapeutics's operating lease liabilities (current) changed year-over-year?
Nektar Therapeutics's operating lease liabilities (current) increased by 3.2% year-over-year, from $21.84M to $22.53M.
What is the long-term trend for Nektar Therapeutics's operating lease liabilities (current)?
Over 5 years (2020 to 2025), Nektar Therapeutics's operating lease liabilities (current) has grown at a 8.1% compound annual growth rate (CAGR), from $13.92M to $20.5M.
What does operating lease liabilities (current) mean?
The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.

Ask your AI about Nektar Therapeutics's operating lease liabilities (current).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude